ACACIA

Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection (ACACIA) is an ongoing multi-site Phase III open-label randomized study conducted in Uganda. The primary objective of the study is to determine whether 24-week cryptococcal meningitis-free survival is improved with liposomal amphotericin in the treatment of asymptomatic cryptococcal antigenemia in addition to standard of care fluconazole therapy.

Funder: National Institutes of Health, National Institute of Allergy and Infectious Diseases.